Count the blasts first (marrow blast percentage decides acute leukemia against myelodysplasia, and the phase of chronic myelogenous leukemia), then the cell line and the hallmark finding, then the patient's fitness and comorbidities before choosing a treatment. Every laboratory value comes with its normal range.
Answers reveal only after you choose. Your score and a breakdown by objective appear at the end, with a review of everything you missed.